Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$11.87 USD
+0.25 (2.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $11.82 -0.05 (-0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 280 | 472 | 504 | 629 | 307 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 0 | 0 | 0 | 0 |
Other Current Assets | 17 | 7 | 4 | 7 | 9 |
Total Current Assets | 308 | 479 | 508 | 636 | 316 |
Net Property & Equipment | 114 | 105 | 101 | 59 | 9 |
Investments & Advances | 0 | 0 | 92 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 229 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 67 | 7 | 8 | 18 | 9 |
Total Assets | 780 | 664 | 777 | 768 | 345 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 33 | 27 | 27 | 14 | 16 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 69 | 52 | 57 | 35 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 110 | 91 | 89 | 55 | 39 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 1 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 12 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 196 | 164 | 156 | 112 | 46 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,594 | 2,069 | 1,795 | 1,487 | 869 |
Retained Earnings | -2,012 | -1,568 | -1,172 | -830 | -571 |
Other Equity | 3 | -1 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 585 | 500 | 622 | 657 | 299 |
Total Liabilities & Shareholder's Equity | 780 | 664 | 777 | 768 | 345 |
Total Common Equity | 585 | 500 | 622 | 657 | 299 |
Shares Outstanding | 255.90 | 187.80 | 156.90 | 146.60 | 126.20 |
Book Value Per Share | 2.28 | 2.66 | 3.96 | 4.48 | 2.37 |
Fiscal Year End for Iovance Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 413 | 356 | 280 | 361 | 251 |
Receivables | 32 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 28 | 18 | 10 | 9 | 10 |
Other Current Assets | 10 | 11 | 17 | 12 | 14 |
Total Current Assets | 482 | 386 | 308 | 383 | 275 |
Net Property & Equipment | 111 | 112 | 114 | 113 | 113 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 295 | 294 | 229 | 224 | 236 |
Deposits & Other Assets | 7 | 7 | 67 | 67 | 67 |
Total Assets | 964 | 870 | 780 | 852 | 757 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 20 | 26 | 33 | 19 | 31 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 62 | 46 | 69 | 61 | 47 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 94 | 83 | 110 | 91 | 89 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 32 | 33 | 17 | 18 | 20 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 1 | 1 | 1 | 1 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 196 | 190 | 196 | 178 | 179 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,990 | 2,805 | 2,594 | 2,579 | 2,360 |
Retained Earnings | -2,222 | -2,125 | -2,012 | -1,896 | -1,782 |
Other Equity | 1 | 0 | 3 | -9 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 769 | 680 | 585 | 674 | 579 |
Total Liabilities & Shareholder's Equity | 964 | 870 | 780 | 852 | 757 |
Total Common Equity | 769 | 680 | 585 | 674 | 579 |
Shares Outstanding | 279.80 | 279.80 | 255.90 | 255.90 | 247.40 |
Book Value Per Share | 2.75 | 2.43 | 2.28 | 2.63 | 2.34 |